Continuous glucose monitoring (CGM) in a non-Icu hospital setting: The patient's journey
- PMID: 37574433
- DOI: 10.1016/j.numecd.2023.06.021
Continuous glucose monitoring (CGM) in a non-Icu hospital setting: The patient's journey
Abstract
Aims: Although consistent data support the outpatient use of continuous glucose monitoring (CGM) to improve glycemic control and reduce hypoglycemic burden, and clinical outcomes, there are limited data regarding its use in the hospital setting, particularly in the non-intensive care unit (non-ICU) setting. The emerging use of CGM in the non-critical care setting may be useful in increasing the efficiency of hospital care and reducing the length of stay for patients with diabetes while improving glycemic control.
Data synthesis: The purpose of this Expert Opinion paper was to evaluate the state of the art and provide a practical model of how CGM can be implemented in the hospital.
Setting: A patient's CGM journey from admission to the ward to the application of the sensor, from patient education on the device during hospitalization until discharge of the patient to maintain remote control.
Conclusions: This practical approach for the implementation and management of CGM in patients with diabetes admitted to non-ICUs could guide hospitals in their diabetes management initiatives using CGM, helping to identify patients most likely to benefit and suggesting how this technology can be implemented to maximize clinical benefits.
Keywords: CGM; Continuous glucose monitoring; Diabetes; Inpatient glucose management; Non-intensive care unit.
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest CI provided advisory board services for Novo Nordisk, Lilly, Abbott, Menarini, Ascensia, and Senseonics, and received speaker fees for Novo Nordisk, Abbott, Ascensia, Lilly, and Boehringer Ingelheim Pharmaceuticals. SC provided advisory board services for Abbott and Novo Nordisk. GDC, EF, FL and MMR provided advisory board services for Abbott. GS received speaker's fee from Novo Nordisk, Servier, Sanofi, Daiichi Sankyo, Teva, Janssen and Eli Lilly, and provided advisory board services for Abbott. ES received speaker's fees from Novo Nordisk and Eli Lilly and provided advisory board services for Abbott. AC received grants from Astra Zeneca, Lilly, Novo-Nordisk. He also received speaker fees, and provided advisory board services for Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Lilly, Merck Sharp & Dhome, Menarini, Novo-Nordisk, Sanofi, Sigma-Tau, Takeda. No other potential conflicts of interest relevant to this article were reported. The sponsor had no role in the design, execution, interpretation, or writing of this review.
Publication types
LinkOut - more resources
Full Text Sources